Background: The benefit of adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma (ICC)
Introduction
Over recent decades, the incidence and mortality of intrahepatic cholangiocarcinoma (ICC) has dramatically increased both in the United States and worldwide. [1] [2] [3] [4] Patients with unresectable ICC have a 5-year survival of 5-10%, and only a minority of patients are candidates for surgery. 5 Even attempts at curativeintent resection are associated with poor outcomes, with estimated overall 5-year survival of 25-30%. 1, [6] [7] [8] The poor longterm prognosis of patients with ICC is related, in part, to the high incidence of recurrence. In fact, up to 70% of patients have been reported to develop a recurrence within 2 years of surgery. 9 While the most common site for initial recurrence after resection of ICC is intrahepatic, up to 50% of patients will develop extrahepatic disease. 10 In addition, when recurrence occurs prognosis is usually poor. Given the generally poor outcomes following surgery alone for patients with ICC, systemic therapy is frequently considered in the adjuvant setting. Current national guidelines recommend adjuvant chemotherapy only for patients with residual disease or nodal metastasis. In contrast, recommendations for patients who undergo a margin-negative, node-negative resection are ambiguous, and include observation, clinical trials, or consideration of adjuvant chemotherapy. 11, 12 Given the relative rarity of ICC, evidence to support the use of adjuvant chemotherapy has been extrapolated from phase II trials of mixed hepatobiliary malignancies or retrospective small single institutional series of ICC patients. 5, [13] [14] [15] The main phase III trial on the use of systemic therapy for advanced biliary malignancies investigated the use of gemcitabine mono-therapy versus doublet therapy with gemcitabine plus cisplatin. 16 However, this trial included patients with advanced inoperable disease who were not surgical candidates. Recently, two randomized clinical trials presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting reported different conclusions. Specifically, in a study examining Gemox versus surveillance following surgery of localized biliary tract cancer, the authors reported the results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. This study concluded that adjuvant chemotherapy for biliary tract cancer with GEMOX was feasible and associated with expected toxicities and no deterioration of health-related quality of life (HrQoL); however, there were no significant differences in recurrence-free survival between Gemox and surveillance. 17 In contrast, in another study investigating adjuvant capecitabine for biliary tract cancer in the BILCAP randomized trial, the authors reported that capecitabine improved overall survival for biliary tract cancer when used as an adjuvant therapy. 18 Whether these data are relevant to the adjuvant setting remains unknown.
In current clinical practice, commonly used therapies for ICC in the adjuvant setting include cisplatin-, gemcitabine-, or fluoropyrimidine-based regimens. 11, 13, 15, 16 The benefit of adjuvant chemotherapy following curative-intent hepatectomy remains, however, poorly understood, and consequently is often subject to national norms and provider or institutional preferences. Therefore, the objective of the current study was to characterize the overall pattern of utilization of adjuvant therapy among a large cohort of patients who underwent curativeintent resection of ICC. Specifically, the study sought to define the survival benefit associated with adjuvant chemotherapy following hepatectomy for ICC, as well as identify specific subsets of patients who may benefit the most from adjuvant chemotherapy.
Materials and methods

Study population and data collection
Patients undergoing curative-intent hepatectomy for histologically confirmed ICC between the years 1990 and 2015 were identified from a multi-institutional database from 14 major hepatobiliary centers in North America, Europe, Australia, and Asia (Supplementary Table 1 ). Cholangiocarcinoma with a significant intrahepatic component with or without a direct involvement of the confluence were defined as ICC. Intrahepatic mass lesions with hilar duct involvement were excluded from the study when the center of the liver mass was located between the right side of the umbilical portion of the left portal vein and the left side of the right posterior portal. 19, 20 Demographic variables were collected including age, gender, American Society of Anesthesiologist (ASA) score and BMI. Relevant clinical variables included preexisting hepatobiliary disease, presence of jaundice or cirrhosis, extent of malignancy in liver, and receipt (and type) of systemic therapy. Operative details included type and extent of hepatectomy, associated procedures (vascular resection, bile duct resection, margin re-resection) performance of lymphadenectomy, operative time, and estimated blood loss. Histopathologic tumor characteristics included size, number of lesions, lymph node involvement, margin status, histological grade, morphologic type, perineural, biliary, or vascular invasion, and extension to other organs. Institution specific final histopathological reports were used to determine nodal and margin status and variables within the database (AJCC staging and tumor characteristics) were standardized across institutions as well as throughout the study period. Major hepatectomy was defined as the resection of three or more liver segments according to Couinaud's classification. 21 Tumor stage was classified using the American Joint Committee on Cancer (AJCC) 8th edition staging system. 22 Primary outcomes and statistical analysis The primary outcome was overall survival (OS), which was calculated from the date of surgery. Descriptive statistics were calculated using Student's t-test, Wilcoxon rank sum, or Chisquare tests, as appropriate for normally or non-normally distributed data. OS time was calculated using the KaplanMeier method and compared between the two patient groups using the logrank test. Univariable and multivariable logistic regression analyses were used to identify predictors of adjuvant chemotherapy use. Variables that had a P-value <0.1 on univariable analyses were included in the final multivariable model. Multivariable cox regression analysis was used to examine the impact of adjuvant chemotherapy on overall survival, after adjusting for demographic, clinical, operative, and pathologic characteristics. All analyses were performed using STATA version 12 (StataCorp, College Station, TX), with two-sided tests and alpha set at 0.05. The institutional review board of each participating institution approved the study protocol.
Results
Patient characteristics
Among the 1209 patients identified, patients who underwent a palliative procedure (n = 5) and patients without operative details (n = 50) were excluded, leaving 1154 ICC patients who underwent curative-intent resection in the analytic cohort. Differences in demographic, clinical, operative, and pathologic characteristics among the entire cohort, and in patients who did versus did not receive adjuvant chemotherapy are described in Tables 1a and 1b . Characteristics of adjuvant therapy for the entire cohort are listed in Table 2 . While 149 (43%) patients received single agent chemotherapy and 187 (54%) had two agents, only a minority (n = 11, 3%) received a combination of three or more drugs. Independent factors associated with receipt of adjuvant chemotherapy are shown in Table 3 .
Adjuvant chemotherapy and AJCC staging system 8th edition Patients with T2/T3/T4 disease remained roughly twice as likely to receive adjuvant therapy compared with patients who had T1a/T1b disease (OR 2.5, 95%CI 1.89-3.23; P < 0.001). Of note, while the presence of N1 disease was associated with a slightly increased odd of receiving adjuvant therapy compared with N0 disease (OR 1.47, 95%CI 0.93-2.35; P = 0.10), NX patients were less likely to receive adjuvant therapy compared with N0 patients (OR 0.52, 95%CI 0.35-0.78; P < 0.001). Of note, independent of clinical factors, adjuvant therapy administration did not increase across the time periods examined (reference, 1990-1999: 1999-2010 Figure S1 ). In contrast, patients with other high-risk biologic features did derive a benefit from chemotherapy. Specifically, among patients with T2-T3-T4 tumors, 5-year OS was 37% (95%CI, 28.9-44.4) versus 30% (95%CI, 23.8-35.6) among patients who did and did not receive adjuvant therapy, respectively (p = 0.006) (Fig. 1a) . Similarly, patients who had an ICC tumor with a PI/MF + PI morphological subtype derived a marked benefit from chemotherapy (5-year OS: no-chemotherapy, 37%, 95%CI 24.8-48.8 vs. chemotherapy 8%, 95%CI 0.9-25.0; p < 0.001) (Fig. 1b) . Among patients with N1 disease, patients who received adjuvant chemotherapy tended to have a better 5-year OS (adjuvant therapy: 18%, 95%CI 9.0-30.1 vs. no adjuvant therapy: 12%, 95%CI 3.9-24.4; P = 0.050) (Fig. 1c) . In fact, on cox regression analysis, the association between adjuvant chemotherapy and improved survival was strongest among patients with T3/T4 tumors (0.437, 95%CI 0.236-0.808, P < 0.01) and N1 disease (HR 0.244, 95%CI 0.130-0.457, P < 0.001), however patients with positive surgical margins did not seem to benefit (HR 0.578, 95%CI 0.259-1.29, P = 0.18). A sensitivity analysis was performed excluding patients lost at the follow-up during the first year after surgery to avoid the possibly confounding effect on the survival of patients in the adjuvant chemotherapy group with an inadequate follow-up. The sensitivity analyses confirmed the same association of adjuvant therapy with long-term outcome (Table S2 , Figures S2-S6 ).
Discussion
The current study demonstrates that adjuvant chemotherapy does not appear to benefit all patients who undergo resection of ICC. Perhaps more importantly, adjuvant chemotherapy was associated with a decreased risk of death long-term among patients with certain pathologic features. Specifically, the benefit of (25) adjuvant therapy was most pronounced among patients with more adverse prognostic features such as advanced T stage, the Periductal Infiltrating or Mass-forming and Periductal Infiltrating morphological subtype, and lymph node metastasis. Adjuvant therapy was utilized in 39% of patients undergoing curative-intent resection for ICC. Receipt of adjuvant therapy was associated with certain clinicopathologic characteristics. For example, while ICC tumor size and surgical margin status were not associated with receipt of adjuvant therapy, Periductal Infiltrating or Mass-forming and Periductal Infiltrating morphological types, perineural invasion, vascular resection, liver capsule involvement, intrahepatic metastasis, and poorlyundifferentiated ICC did impact the likelihood of a patient to receive post-operative therapy. These data are consistent with the expectation that patients with more advanced disease would be more likely to be offered adjuvant therapy. However, it is important to note that the utilization of adjuvant chemotherapy was less than 50% even among high-risk patients. For example, while previous studies have demonstrated that lymph node metastasis was one of the strongest predictors of adverse longterm outcomes following resection of ICC, less than one-half of N1 patients received adjuvant therapy. 23, 24 In contrast, patients with Periductal Infiltrating or Mass-forming and Periductal Infiltrating ICC morphological subtypes had the highest incidence of adjuvant chemotherapy (53%). Prospective data on the benefit of adjuvant systemic therapy among patients with resected ICC are limited. 25 Two randomized trials of adjuvant chemotherapy that included patients with ICC did not demonstrate a difference in long-term survival comparing patients who underwent surgery-alone versus surgery plus adjuvant therapy. 26, 27 The results of these studies are difficult to interpret, however, as both reports included patients with a wide variety of biliary tract malignancies. In the current study, adjuvant therapy was not associated with a survival benefit when the entire cohort was analyzed. Importantly, adjuvant therapy was associated with a survival benefit in specific subsets of patients with high-risk features (Fig. 1a-c) . Using data from the National Cancer Database, Miura et al. had similarly reported no difference in median OS following resection of ICC among the observation versus chemotherapy groups (23 vs. 20 months, P = 0.09). 28 However, the authors did note a survival benefit among subgroups of patients with N1 disease (19.8 vs. 10.7 months, P < 0.001) and T3/T4 tumors (21.3 vs. 15.6 months, P < 0.001). In a separate systematic review, Horgan et al. reported no improvement in survival associated with adjuvant therapy overall (OR 0.75, 95%CI 0.55-1.01, P = 0.06), yet did note a benefit among patients with N1 disease (OR 0.49, 95%CI 0.30-0.80, P = 0.004). 29 Collectively, these data strongly suggest that while the benefit of adjuvant therapy may only be modest when all patients with ICC are treated, certain high-risk subgroups may indeed derive a survival advantage from postoperative systemic treatment.
In the current study, while patients with lymph node metastasis (N1) did not have an increased likelihood to receive adjuvant chemotherapy (OR 1.05, p = 0.83), patients who did not undergo lymphadenectomy (NX) did have a much lower chance to receive chemotherapy (OR 0.47, p < 0.001) compared with node negative patients. The lower chance to receive adjuvant therapy among NX patients was interesting, as the presence of lymph node metastasis is one of the most important predictors of survival. 12, [30] [31] [32] [33] [34] The routine performance of lymphadenectomy for ICC remains controversial, however, with different centers reporting variable rates of lymphadenectomy. 12, 30, [35] [36] [37] Although the evidence to suggest a survival benefit for lymphadenectomy is varied, 34, 35, 37, 38 accurate nodal staging may assist in informing post-operative treatment. In particular, data from the current study demonstrated that adjuvant chemotherapy tended to be associated with a survival benefit among patients with N1 disease. In fact, patients with N1 disease who received adjuvant therapy had a decreased risk of death at 5-years compared with N1 patients who were simply observed following surgery (HR 0.70; p = 0.05), and this result was more pronounced on multivariable analysis (HR 0.244, 95%CI 0.130-0.457, P < 0.001). To this end, current national guidelines recommend adjuvant chemotherapy for patients with nodal metastasis. 11, 12 In the present study, only 48% of patients underwent a formal lymphadenectomy, with patients who had a lymphadenectomy being more likely to receive adjuvant chemotherapy. Given the prognostic and treatment-related adjuvant implications of adequate nodal staging, regional routine lymphadenectomy should strongly be considered as a part of surgical therapy for ICC. 12 There are several limitations that need to be considered when interpreting this data. First, given the rarity of ICC, an international, multi-institutional database that included patients from multiple decades was utilized in order to accumulate a sufficient sample size. As such, there was likely some heterogeneity regarding treatment approaches and use of adjuvant therapy. However, most patients in the study underwent surgery within the last six years. Second, like any retrospective study, unmeasured confounding and selection bias could influence the results, as patients who experience early morbidity or mortality are less likely to receive chemotherapy. To address this limitation, both multivariable and stratified analyses were performed to specifically examine the impact of adjuvant therapy among different subgroups.
In conclusion, utilizing one of the largest international, multi-institutional cohorts of patients undergoing curative hepatectomy for ICC, this study demonstrated that although adjuvant chemotherapy did not influence the long-term prognosis of all ICC patients following surgical resection, it was associated with a potential survival benefit in select subgroups of patients at increased risk for recurrence, specifically patients with advanced tumors. These findings highlight the importance of accurate pathologic staging, including a formal lymph node evaluation, in the multimodality treatment of ICC patients. Future studies will further need to better define clinicopathologic and molecular markers to identify those patients who are most likely to benefit from adjuvant systemic therapy following resection of ICC.
